| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
|
J Clin Oncol
|
2011
|
6.18
|
|
2
|
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.
|
Nat Genet
|
2012
|
4.82
|
|
3
|
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
|
Gut
|
2012
|
4.51
|
|
4
|
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
|
Gut
|
2012
|
2.36
|
|
5
|
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.
|
Gastroenterology
|
2011
|
2.36
|
|
6
|
Oncogenic pathway combinations predict clinical prognosis in gastric cancer.
|
PLoS Genet
|
2009
|
1.96
|
|
7
|
Whole genome analysis for liver metastasis gene signatures in colorectal cancer.
|
Int J Cancer
|
2007
|
1.85
|
|
8
|
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
|
Breast Cancer Res Treat
|
2007
|
1.68
|
|
9
|
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
|
J Clin Oncol
|
2012
|
1.67
|
|
10
|
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
|
Eur J Cancer
|
2011
|
1.60
|
|
11
|
CD44-SLC1A2 gene fusions in gastric cancer.
|
Sci Transl Med
|
2011
|
1.59
|
|
12
|
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
|
Ann Surg Oncol
|
2007
|
1.53
|
|
13
|
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
|
Cancer
|
2011
|
1.49
|
|
14
|
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.
|
PLoS One
|
2008
|
1.47
|
|
15
|
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors.
|
Support Care Cancer
|
2013
|
1.42
|
|
16
|
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer.
|
Gut
|
2012
|
1.42
|
|
17
|
Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
|
Exp Ther Med
|
2011
|
1.26
|
|
18
|
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea.
|
Cancer Res Treat
|
2009
|
1.25
|
|
19
|
Intermediate dose 5-fluorouracil-induced encephalopathy.
|
Jpn J Clin Oncol
|
2006
|
1.23
|
|
20
|
Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene.
|
Cancer Res
|
2008
|
1.21
|
|
21
|
Retracted
Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
|
Yonsei Med J
|
2012
|
1.20
|
|
22
|
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.
|
Oncology
|
2011
|
1.17
|
|
23
|
The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer.
|
J Surg Oncol
|
2009
|
1.17
|
|
24
|
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
|
Eur J Cancer
|
2012
|
1.11
|
|
25
|
Prediction of recurrence of early gastric cancer after curative resection.
|
Ann Surg Oncol
|
2009
|
1.10
|
|
26
|
A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis.
|
Oncology
|
2011
|
1.10
|
|
27
|
Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
|
Breast Cancer Res Treat
|
2010
|
1.07
|
|
28
|
Brain metastases from colorectal carcinoma: prognostic factors and outcome.
|
J Neurooncol
|
2010
|
1.07
|
|
29
|
A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
|
Cancer
|
2010
|
1.06
|
|
30
|
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
|
Pharmacogenet Genomics
|
2006
|
1.04
|
|
31
|
Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression.
|
Clin Cancer Res
|
2006
|
1.04
|
|
32
|
Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer.
|
Genomics
|
2007
|
1.01
|
|
33
|
Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
|
Cancer Lett
|
2004
|
0.99
|
|
34
|
Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells.
|
BMC Genomics
|
2012
|
0.98
|
|
35
|
Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
|
Oncology
|
2007
|
0.98
|
|
36
|
Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray.
|
Int J Oncol
|
2003
|
0.98
|
|
37
|
Kidney Cancer Working Group report.
|
Jpn J Clin Oncol
|
2010
|
0.97
|
|
38
|
Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma.
|
Eur Urol
|
2003
|
0.97
|
|
39
|
The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up.
|
Ann Surg Oncol
|
2010
|
0.97
|
|
40
|
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
|
Cancer Chemother Pharmacol
|
2013
|
0.96
|
|
41
|
Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design.
|
Cancer Chemother Pharmacol
|
2010
|
0.96
|
|
42
|
SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis.
|
BMC Bioinformatics
|
2008
|
0.95
|
|
43
|
Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations.
|
Oncologist
|
2007
|
0.95
|
|
44
|
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
|
Target Oncol
|
2013
|
0.95
|
|
45
|
Statistical methods of translating microarray data into clinically relevant diagnostic information in colorectal cancer.
|
Bioinformatics
|
2004
|
0.95
|
|
46
|
Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization.
|
BMC Genomics
|
2007
|
0.95
|
|
47
|
Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute.
|
J Surg Oncol
|
2007
|
0.94
|
|
48
|
Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss.
|
Breast Cancer Res Treat
|
2005
|
0.94
|
|
49
|
Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients.
|
Clin Cancer Res
|
2005
|
0.94
|
|
50
|
Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics.
|
AJR Am J Roentgenol
|
2011
|
0.93
|
|
51
|
Green tea consumption and stomach cancer risk: a meta-analysis.
|
Epidemiol Health
|
2010
|
0.93
|
|
52
|
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.92
|
|
53
|
Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density.
|
Magn Reson Med
|
2013
|
0.92
|
|
54
|
Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1.
|
J Gen Virol
|
2012
|
0.92
|
|
55
|
Clinical value of ezrin expression in primary osteosarcoma.
|
Cancer Res Treat
|
2009
|
0.92
|
|
56
|
Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer.
|
Radiother Oncol
|
2010
|
0.92
|
|
57
|
Molecular basis of the differences between normal and tumor tissues of gastric cancer.
|
Biochim Biophys Acta
|
2007
|
0.92
|
|
58
|
A densely interconnected genome-wide network of microRNAs and oncogenic pathways revealed using gene expression signatures.
|
PLoS Genet
|
2011
|
0.92
|
|
59
|
Wernicke's encephalopathy in advanced gastric cancer.
|
Cancer Res Treat
|
2010
|
0.91
|
|
60
|
A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.91
|
|
61
|
High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients.
|
World J Surg Oncol
|
2014
|
0.91
|
|
62
|
Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase.
|
Jpn J Cancer Res
|
2002
|
0.90
|
|
63
|
Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
|
J Cancer Res Clin Oncol
|
2010
|
0.89
|
|
64
|
Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
|
Mol Cancer Res
|
2008
|
0.89
|
|
65
|
A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma.
|
Yonsei Med J
|
2003
|
0.88
|
|
66
|
Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool.
|
Ann Surg Oncol
|
2013
|
0.87
|
|
67
|
Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray.
|
Clin Cancer Res
|
2005
|
0.87
|
|
68
|
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
|
Int J Oncol
|
2013
|
0.87
|
|
69
|
Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy.
|
Radiother Oncol
|
2012
|
0.87
|
|
70
|
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
|
Invest New Drugs
|
2011
|
0.87
|
|
71
|
Prognosis of pN3 stage gastric cancer.
|
Cancer Res Treat
|
2009
|
0.87
|
|
72
|
Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
|
Oncology
|
2011
|
0.86
|
|
73
|
The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation.
|
Mol Cancer Res
|
2013
|
0.86
|
|
74
|
Novel and simple transformation algorithm for combining microarray data sets.
|
BMC Bioinformatics
|
2007
|
0.86
|
|
75
|
Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
|
Cancer Chemother Pharmacol
|
2011
|
0.86
|
|
76
|
Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma.
|
Int J Hyperthermia
|
2010
|
0.86
|
|
77
|
Expression of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductal growth type of cholangiocarcinoma.
|
Am J Gastroenterol
|
2004
|
0.85
|
|
78
|
Spearman's footrule as a measure of cDNA microarray reproducibility.
|
Genomics
|
2004
|
0.85
|
|
79
|
Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma.
|
Exp Mol Pathol
|
2012
|
0.84
|
|
80
|
Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor.
|
J Radiat Res
|
2011
|
0.84
|
|
81
|
Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma.
|
J Gastroenterol Hepatol
|
2008
|
0.84
|
|
82
|
Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
|
Anticancer Drugs
|
2011
|
0.84
|
|
83
|
Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression.
|
Cancer Sci
|
2010
|
0.84
|
|
84
|
MMP-2 as a putative biomarker for carcinomatosis in gastric cancer.
|
Hepatogastroenterology
|
2012
|
0.84
|
|
85
|
In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.
|
Genomics
|
2008
|
0.84
|
|
86
|
Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2007
|
0.84
|
|
87
|
Prevalence and associated factors of psychological distress among Korean cancer patients.
|
Gen Hosp Psychiatry
|
2011
|
0.84
|
|
88
|
Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.
|
Jpn J Clin Oncol
|
2013
|
0.83
|
|
89
|
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2007
|
0.83
|
|
90
|
Bilateral breast cancer: differential diagnosis using histological and biological parameters.
|
Jpn J Clin Oncol
|
2007
|
0.83
|
|
91
|
Subtelomeric DNA methylation and telomere length in human cancer cells.
|
Cancer Lett
|
2009
|
0.83
|
|
92
|
Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.
|
Cancer Res Treat
|
2010
|
0.83
|
|
93
|
Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents.
|
Oncol Rep
|
2007
|
0.83
|
|
94
|
Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer.
|
Ann Surg Oncol
|
2014
|
0.83
|
|
95
|
Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis.
|
Jpn J Clin Oncol
|
2011
|
0.83
|
|
96
|
Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions.
|
BMC Bioinformatics
|
2008
|
0.82
|
|
97
|
Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
|
J Clin Pathol
|
2013
|
0.82
|
|
98
|
Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.
|
J Radiat Res
|
2012
|
0.82
|
|
99
|
Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials.
|
Cancer Res Treat
|
2009
|
0.82
|
|
100
|
Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma.
|
Cancer Chemother Pharmacol
|
2013
|
0.82
|
|
101
|
Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients.
|
Cancer Lett
|
2009
|
0.82
|
|
102
|
Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy.
|
Oncol Rep
|
2010
|
0.82
|
|
103
|
Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
|
Invest New Drugs
|
2012
|
0.82
|
|
104
|
The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization.
|
Int J Mol Med
|
2004
|
0.82
|
|
105
|
The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma.
|
Yonsei Med J
|
2013
|
0.82
|
|
106
|
PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.
|
Oncology
|
2014
|
0.82
|
|
107
|
Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
|
Oncology
|
2011
|
0.81
|
|
108
|
Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy.
|
Ann Surg
|
2016
|
0.81
|
|
109
|
Gastrointestinal stromal tumor of the rectum: an analysis of seven cases.
|
Surg Today
|
2007
|
0.81
|
|
110
|
A weighted sample size for microarray datasets that considers the variability of variance and multiplicity.
|
J Biosci Bioeng
|
2009
|
0.81
|
|
111
|
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
|
Invest New Drugs
|
2013
|
0.81
|
|
112
|
A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer.
|
Oncology
|
2006
|
0.81
|
|
113
|
Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer.
|
Arch Surg
|
2008
|
0.81
|
|
114
|
Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction.
|
Yonsei Med J
|
2009
|
0.81
|
|
115
|
The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites.
|
J Cancer Res Clin Oncol
|
2009
|
0.80
|
|
116
|
Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia.
|
Yonsei Med J
|
2007
|
0.80
|
|
117
|
Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites.
|
Cancer Res Treat
|
2010
|
0.80
|
|
118
|
Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators.
|
J Cancer Res Clin Oncol
|
2009
|
0.80
|
|
119
|
Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice.
|
Melanoma Res
|
2013
|
0.80
|
|
120
|
Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.
|
Cancer Res Treat
|
2012
|
0.80
|
|
121
|
Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA.
|
Cancer Sci
|
2006
|
0.80
|
|
122
|
Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer.
|
Pathology
|
2014
|
0.80
|
|
123
|
Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study.
|
J Surg Oncol
|
2012
|
0.80
|
|
124
|
Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation.
|
Radiother Oncol
|
2013
|
0.79
|
|
125
|
Long-term survival after surgical resection for liver metastasis from gastric cancer: two case reports.
|
Cancer Res Treat
|
2006
|
0.79
|
|
126
|
Prognostic index reflecting genetic alteration related to disease-free time for gastric cancer patient.
|
Oncol Rep
|
2009
|
0.79
|
|
127
|
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
|
Cancer Chemother Pharmacol
|
2014
|
0.79
|
|
128
|
Increased alternative lengthening of telomere phenotypes of telomerase-negative immortal cells upon trichostatin--a treatment.
|
Anticancer Res
|
2013
|
0.79
|
|
129
|
Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer.
|
J Surg Oncol
|
2009
|
0.79
|
|
130
|
A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.
|
Am J Clin Oncol
|
2010
|
0.78
|
|
131
|
Changing treatment patterns in elderly patients with resectable colon cancer.
|
Asia Pac J Clin Oncol
|
2012
|
0.78
|
|
132
|
Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas.
|
Leuk Lymphoma
|
2004
|
0.78
|
|
133
|
Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer.
|
Cancer Lett
|
2008
|
0.78
|
|
134
|
Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia.
|
Cancer Genet Cytogenet
|
2010
|
0.78
|
|
135
|
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2007
|
0.78
|
|
136
|
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
|
BMC Cancer
|
2012
|
0.78
|
|
137
|
Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis.
|
Oncol Rep
|
2010
|
0.78
|
|
138
|
Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells.
|
Int J Mol Med
|
2013
|
0.78
|
|
139
|
Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung.
|
Yonsei Med J
|
2013
|
0.78
|
|
140
|
Variation of the 3' telomeric overhang lengths in human cells.
|
Cancer Lett
|
2008
|
0.78
|
|
141
|
Methylation status of lamin A/C in gastric cancer cell lines.
|
Hepatogastroenterology
|
2012
|
0.78
|
|
142
|
Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia.
|
Ann Surg
|
2017
|
0.77
|
|
143
|
Treatment of recurrent hepatocellular carcinoma after liver transplantation.
|
Asia Pac J Clin Oncol
|
2011
|
0.77
|
|
144
|
EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.
|
Yonsei Med J
|
2012
|
0.77
|
|
145
|
Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer.
|
Breast Cancer Res Treat
|
2007
|
0.77
|
|
146
|
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2011
|
0.77
|
|
147
|
A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer.
|
Gynecol Oncol
|
2012
|
0.77
|
|
148
|
Systematic analysis of cDNA microarray-based CGH.
|
Int J Mol Med
|
2006
|
0.77
|
|
149
|
Body fluid MMP-2 as a putative biomarker in metastatic breast cancer.
|
Oncol Lett
|
2012
|
0.77
|
|
150
|
Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.
|
Radiother Oncol
|
2008
|
0.77
|
|
151
|
Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.
|
PLoS One
|
2012
|
0.77
|
|
152
|
Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients.
|
Int J Mol Med
|
2005
|
0.77
|
|
153
|
Clinicopathological features and prognostic significance of HER2 expression in gastric cancer.
|
Oncology
|
2014
|
0.77
|
|
154
|
A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status.
|
Oncology
|
2009
|
0.77
|
|
155
|
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
|
Clin Nucl Med
|
2017
|
0.76
|
|
156
|
A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2006
|
0.76
|
|
157
|
PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity.
|
Int J Cancer
|
2014
|
0.76
|
|
158
|
Entropy-based analysis of the non-linear relationship between gene expression profiles of amplified and non-amplified RNA.
|
Int J Mol Med
|
2007
|
0.76
|
|
159
|
Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
|
Urology
|
2013
|
0.75
|
|
160
|
A locally advanced breast cancer with difficult differential diagnosis of carcinosarcoma and atypical medullary carcinoma, which had poor response to adriamycin- and taxane-based neoadjuvant chemotherapy: a case report.
|
Cancer Res Treat
|
2007
|
0.75
|
|
161
|
PIK3CA mutations in hepatocellular carcinoma in Korea.
|
Yonsei Med J
|
2013
|
0.75
|
|
162
|
S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer.
|
Korean J Intern Med
|
2008
|
0.75
|
|
163
|
Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience.
|
BMC Cancer
|
2012
|
0.75
|
|
164
|
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
|
Invest New Drugs
|
2010
|
0.75
|
|
165
|
A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.
|
Invest New Drugs
|
2009
|
0.75
|
|
166
|
An attempt for combining microarray data sets by adjusting gene expressions.
|
Cancer Res Treat
|
2007
|
0.75
|
|
167
|
Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
|
Jpn J Clin Oncol
|
2009
|
0.75
|
|
168
|
Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on Microarray-CGH.
|
Int J Mol Med
|
2007
|
0.75
|
|
169
|
Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells.
|
Anticancer Res
|
2013
|
0.75
|
|
170
|
A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane.
|
Cancer Res Treat
|
2002
|
0.75
|
|
171
|
A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
|
Invest New Drugs
|
2010
|
0.75
|
|
172
|
Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
|
173
|
G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern.
|
Cancer Lett
|
2009
|
0.75
|
|
174
|
Changes of Telomerase Activity and Proliferation by Inhibition of Reverse Transcriptase Activity in Human Cancer Cell.
|
Cancer Res Treat
|
2002
|
0.75
|
|
175
|
Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy.
|
Oncology
|
2016
|
0.75
|
|
176
|
Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials.
|
Cancer Chemother Pharmacol
|
2008
|
0.75
|
|
177
|
Vascular soft-tissue sarcomas: a prognostic model from a retrospective single-center study.
|
Oncology
|
2014
|
0.75
|
|
178
|
Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy.
|
Acta Oncol
|
2007
|
0.75
|
|
179
|
Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer.
|
Int J Oncol
|
2009
|
0.75
|
|
180
|
cDNA Microarray Experiment: Design Issues in Early Stage and the Need of Normalization.
|
Cancer Res Treat
|
2003
|
0.75
|
|
181
|
Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer.
|
Cancer Res Treat
|
2003
|
0.75
|
|
182
|
Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phospho-specific flow cytometry.
|
Anal Quant Cytopathol Histpathol
|
2012
|
0.75
|
|
183
|
Fabrication of high quality cDNA microarray using a small amount of cDNA.
|
Int J Mol Med
|
2004
|
0.75
|
|
184
|
Identification of significant regional genetic variations using continuous CNV values in aCGH data.
|
Genomics
|
2009
|
0.75
|